Don’t Wait—Uncover the Clinical Endpoints that Will Matter to Payers and HCPs
PM360
APRIL 7, 2023
This is critical because the disease burden is often not quantified for certain populations or sub-populations indicated for CGT or certain orphan drugs. This option grows more critical as new therapies become available with price tags as high as $3.5 million for the new hemophilia gene therapy.
52 
Let's personalize your content